Refractory Acute Lymphoblastic Leukemia Recruiting Phase 2 Trials for Muromonab (DB00075)

Also known as: Acute Lymphoblastic Leukemia, Refractory / Acute, refractory Lymphoblastic Leukemia / Acute, refractory Lymphocytic leukaemia / Acute, refractory Lymphocytic Leukemia / Acute lymphocytic leukemia refractory / Acute, refractory Lymphoblastic Leukaemia / Acute lymphocytic leukaemia refractory / Refractory Acute lymphoblastic leukaemia

IndicationStatusPhase
DBCOND0058624 (Refractory Acute Lymphoblastic Leukemia)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03263572Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic LeukemiaTreatment
NCT03147612Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic LeukemiaTreatment
NCT02143414Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic LeukemiaTreatment